A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time.
Latest Information Update: 13 Apr 2020
Price :
$35 *
At a glance
- Drugs Hydrocodone (Primary)
- Indications Back pain; Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Cephalon; Teva Branded Pharmaceutical Products R&D
- 30 Dec 2011 Actual patient number (391) and trial location (USA) added as reported by ClinicalTrials.gov.
- 30 Dec 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 30 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.